A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Secondary Progressive Multiple Sclerosis
Interventions
DRUG

Foralumab

"Foralumab nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).~Each Unidose device contains foralumab nasal solution, supplied at either 25 μg foralumab or 50 μg foralumab, sufficient for administration into a single nare."

OTHER

Placebo

Foralumab placebo nasal solution is a preservative-free, sterile, clear, colorless-to-slightly-yellow solution filled in an Aptar Unidose nasal atomizer device. Each Unidose device contains 0.13 mL foralumab placebo nasal solution, sufficient for administration to a single nare. Two Aptar Unidose devices will be used for a single dose (one device per nare).

Trial Locations (7)

10021

RECRUITING

Cornell Weill Medical Center, New York

14202

RECRUITING

University of Buffalo, Buffalo

19107

RECRUITING

Thomas Jefferson University Hospital, Philadelphia

21287

RECRUITING

Johns Hopkins, Baltimore

06473

RECRUITING

Yale, North Haven

02115

RECRUITING

Brigham and Women's Hospital, Boston

01655

RECRUITING

University of Massachusetts, Worcester

All Listed Sponsors
lead

Tiziana Life Sciences LTD

INDUSTRY

NCT06292923 - A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients | Biotech Hunter | Biotech Hunter